MedRhythms is planning to soon open a pilot clinical trial to assess the safety and efficacy of its MR-004, its investigational product that uses rhythmic sounds to improve walking abilities in people with multiple sclerosis (MS), the company announced.
MedRhythms is a digital therapeutics company exploring the use of sensors, software, and music to aid in walking rehabilitation.
More than 50 clinical research studies have reported improvements in movement based on the use of rhythmic auditory stimulation through music, the company reports. These studies were conducted in people with diseases or conditions affecting the brain, including MS, Parkinson’s disease, cerebral palsy, and stroke.
Rhythmic auditory stimulation directly stimulates the brain to activate a mechanism known as “entrainment” — a neurologic process in which the brain’s auditory and motor regions are coupled, MedRhythms states on its website. Entrainment can enhance neuroplasticity (the brain’s ability to strengthen pre-existing neural connections, allowing a person to acquire skills over time), and induce neuroplastic changes that produce improved motor outcomes.
Music, the company proposes, induces the neurological connections needed for the positive re-wiring of the brain.
MR-004 is the company’s pipeline product, based on rhythmic auditory stimulation, being developed for walking rehabilitation in MS.
“I’ve conducted many trials on interventions to improve walking in those living with MS, including the compelling impacts of rhythmic cueing in this population,” Francois Bethoux, MD, a paid advisory member to MedRhythms and who will lead the trial, said in the press release.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?